ticagrelor / Generic mfg. - LARVOL DELTA

The effect of medical therapies for subthreshold abdominal aortic aneurysm growth and mortality: a network meta-analysis of randomized controlled trials. (PubMed, Interdiscip Cardiovasc Thorac Surg) - "Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality. The absence of statistically significant benefit may reflect underpowered datasets rather than definitive treatment inefficacy. Future large-scale, appropriately powered randomized controlled trials evaluating emerging medical treatments are required to accurately assess their clinical potential."

Journal • Retrospective data • Cardiovascular

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases. (PubMed, Am J Case Rep) - "He underwent emergency percutaneous coronary intervention and was started on dual antiplatelet therapy (aspirin 81 mg/day, and ticagrelor 90 mg twice daily)...Our second case was a 66-year-old man who received single doses of ticagrelor (180 mg) and eptifibatide (180 mcg/kg) during an attempted PCI...Platelet reactivity increased immediately following the procedure; bleeding was stabilized, and no further blood products were required after postoperative day 1. CONCLUSIONS TPE may be an effective novel option for emergency removal of circulating ticagrelor in refractory bleeding cases."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Ticagrelor and prevention of infective endocarditis in patients at risk: a population-based study (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular

TIMO: Ticagrelor Monotherapy After Stenting (clinicaltrials.gov) - P2 | N=200 | Completed | Sponsor: Vastra Gotaland Region | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2025

Monotherapy • Trial completion • Trial completion date • Cardiovascular • Myocardial Infarction

Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. (PubMed, Biochem Pharmacol) - "Ticagrelor synergistically enhanced the cytotoxicity of Adriamycin (Adr) and Paclitaxel (PTX) in MCF-7/Adr and MCF-7/PTX cells, respectively. In conclusion, Ticagrelor reverses breast cancer MDR by concurrently inhibiting PI3K/AKT/mTOR signaling, downregulating ABCB1 expression and function. Our findings highlight the potential of Ticagrelor as a dual-acting agent that not only targets tumor metastasis but also overcomes chemoresistance, providing a new strategic direction for combination therapy in refractory breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor • ABCB1

Angiography-derived fractional flow reserve- vs usual care-guided percutaneous coronary intervention: interim analysis of the PIONEER IV trial. (PubMed, Eur Heart J) - No abstract available

Journal

Contemporary Trends in High-Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. (PubMed, J Am Heart Assoc) - "Among patients with AMI undergoing PCI, the use of high-potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice."

Journal • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease

Evaluation of Ticagrelor Dosing Guided by Platelet Function Testing Post Neuroendovascular Stenting (SCCM 2026) - "Utilizing PFT to guide dosing of ticagrelor in neuroendovascular patients post stenting showed low thrombotic and bleeding events; in addition, there was no difference in thrombotic and bleeding outcomes based on ticagrelor dose received."

Cardiovascular • Hematological Disorders

Outcomes of Clopidogrel vs Potent P2Y12 Inhibitors in Patients With ACS and AF on OAC (SCCM 2026) - "However, limited data exist on the safety and efficacy of potent P2Y12 inhibitors, such as ticagrelor and prasugrel, when combined with OAC in this population. This study contributes to the small but growing body of literature evaluating combinations of OAC with clopidogrel versus potent P2Y12 inhibitors. It offers some insight into real-world clinical outcomes. Although no statistically significant safety or efficacy differences were observed, the numerically lower rate of MACE in the potent P2Y12 group may reflect enhanced antiplatelet efficacy, warranting further investigation."

Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Thrombosis

Use of Cangrelor and Platelet Reactivity Unit Monitoring in Patients With Acute Ischemic Stroke (SCCM 2026) - "Cangrelor may be a safe alternative antiplatelet agent in patients who could not receive oral P2Y12 inhibitors in acute ischemic stroke. PRU assay monitoring could be considered."

Clinical • Cardiovascular • Ischemic stroke

Impact of Timing of P2Y12 Inhibitor Loading Doses on Revascularization in STEMI (SCCM 2026) - "Of patients loaded in the ED, 98.6% received ticagrelor compared to 69.4% of cardiac catheterization laboratory patients... Compared to patients who received loading doses of P2Y12 inhibitors in the ED, there is no significant difference in revascularization based on TIMI flow score in patients who received their loading dose in the cardiac catheterization laboratory. This may support loading patients in the cardiac catheterization laboratory to prevent delaying further intervention, such as coronary artery bypass grafting, in patients unable to undergo PCI. However, further research is needed to support this finding."

Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Clinical outcomes and missed benefits related to clopidogrel overuse in acute coronary syndrome. (PubMed, J Thromb Thrombolysis) - No abstract available

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

ACUTE CORONARY SYNDROME WITH STENT THROMBOSIS: HEPARIN-INDUCED THROMBOCYTOPENIA WITH FALSE-NEGATIVE SEROTONIN RELEASE ASSAY IN A PATIENT ON TICAGRELOR (ACC 2026) - "Despite aspirin and ticagrelor, he developed recurrent chest pain within 5 hours...After switching to prasugrel, repeat SRA became positive. False-negative SRA results may occur with Ticagrelor. Awareness of this limitation and incorporation of alternative assays with clinical assessment are essential to avoid catastrophic complications from HIT"

Clinical • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia • Thrombosis

ALTERNATIVE STRATEGIES FOR TRANSFUSION-FREE EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION SUPPORT AND DECANNULATION: A JEHOVAH'S WITNESS CASE (ACC 2026) - "She underwent stenting to an ostial right coronary artery lesion and started on aspirin and ticagrelor... Bleeding management without transfusion in ECPR is challenging but achievable. This case demonstrates that multimodal ATS can safely guide ECPR and decannulation in patients who decline transfusions, providing a practical framework for managing severe anemia in similar high-risk scenarios."

Clinical • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

CONCOMITANT STROKE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A PATIENT WITH NEW-ONSET ATRIAL FIBRILLATION (ACC 2026) - "She underwent defibrillation and was started on IV amiodarone and magnesium...New-onset paroxysmal atrial fibrillation prompted initiation of apixaban; aspirin and ticagrelor were switched to clopidogrel... Concurrent stroke and MI with new-onset atrial fibrillation creates competing risks where treatment for one may compromise the other. Risk-benefit discussion and consideration of mortality risk can help guide management."

Clinical • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Myocardial Infarction • Ventricular Tachycardia

ACUTE STEMI FROM CORONARY EMBOLISM IN A YOUNG MALE WITH POLYCYTHEMIA VERA (ACC 2026) - "He was started on aspirin, ticagrelor, statin, and ezetimibe; eptifibatide was stopped due to bleeding...Due to recurrent arterial events, apixaban was started, aspirin stopped, ticagrelor continued. Heart failure therapy and hydroxyurea were continued... PV can cause embolic STEMI without coronary disease. Early recognition and tailored therapy led to stable recovery."

Cardiovascular • Chronic Eosinophilic Leukemia • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hypertension • Myocardial Infarction • Polycythemia Vera • Thrombosis • JAK2

TRIPLE ANTITHROMBOTIC THERAPY WITH TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PCI FOR ACUTE MYOCARDIAL INFARCTION (ACC 2026) - "Background: Triple antithrombotic therapy (TAT), comprising a DOAC, aspirin, and a P2Y12 inhibitor, is recommended for patients with atrial fibrillation (AF) undergoing PCI for acute myocardial infarction (AMI) - for 1 week in low-risk and up to 1 month in high-risk patients. In our real-world analysis, ticagrelor had comparable outcomes to clopidogrel when used as part of TAT, after PCI for AMI in AF/ flutter. Our findings suggest that ticagrelor may be a reasonable alternative, particularly in patients with clopidogrel resistance, warranting further prospective studies."

Clinical • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction

TRENDS AND INSTITUTIONAL VARIATION IN HIGH-POTENCY P2Y12 INHIBITORS PRESCRIPTION AMONG PATIENTS WITH CHRONIC CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION - AN ANALYSIS FROM THE NCDR CATH PCI REGISTRY (ACC 2026) - "Background: This analysis examines prescription patterns of high-potency P2Y12 inhibitors (ticagrelor or prasugrel) versus clopidogrel among patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) in the U.S. This is an observational analysis using the NCDR Cath-PCI registry including patients with CCS undergoing PCI from 2018 to 2024. About one-third of patients with CCS undergoing PCI received high-potency P2Y12 inhibitors at discharge, with wide variability across US institutions. This pattern was influenced by certain patient and procedural factors."

Clinical

TICAGRELOR VS PRASUGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION: A PROPENSITY-SCORE MATCHED ANALYSIS (ACC 2026) - "Among patients following PCI, prasugrel is associated with a significantly lower risk of adverse clinical events than ticagrelor. The benefits of fewer ischemic events with prasugrel did not occur at the expense of an increased risk of bleeding."

Cardiovascular • Ischemic stroke • Myocardial Infarction

NAVIGATING STEMI, PCI, AND ATRIAL FIBRILLATION IN SEVERE HEMOPHILIA A: A THERAPEUTIC BALANCING ACT (ACC 2026) - "He was maintained on DAPT (aspirin and ticagrelor) with prophylactic factor VIII (2,500 IU every other day) and underwent successful PCI to the mid-LAD without bleeding complications. This case highlights the delicate therapeutic balance required when treating STEMI and AF in patients with hemophilia. As hemophilia patients live longer and face rising cardiovascular risk, this case reinforces the need for dedicated research to guide treatment decisions in this population."

Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Myocardial Infarction • Rare Diseases

TEG-6S PLATELET MAPPING ASSAY FOR IDENTIFYING HYPERCOAGULABILITY, ANTIPLATELET RESPONSE, AND 1-YEAR MACE PREDICTION IN ACS AND IS PATIENTS (ACC 2026) - "PA was lower with higher ASA doses (naïve: 70±29%, 81 mg: 28±32%, 325 mg: 17±25%; p<0.001) and with ticagrelor/prasugrel vs. clopidogrel (CLP) (45±30% vs. 69±32%; p<0.001). TEG6s-identified HYP, primarily driven by H-FCS, is linked to increased HPR and 1-year MACE. TEG6s testing shows promise for refining ischemic risk prediction and tailoring therapy, warranting further validation"

Clinical • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Nephrology • Renal Disease

INDIVIDUALIZED BLEEDING RISK WITH LOW-DOSE PRASUGREL VS. CLOPIDOGREL AFTER PCI: A CAUSAL FOREST-BASED MACHINE LEARNING APPROACH (ACC 2026) - "In several East Asian countries, low-dose (LD) prasugrel has been adopted in place of standard-dose prasugrel or ticagrelor. Individualized ARI estimation can inform P2Y12 inhibitor selection and improve safety, particularly in East Asians."

Clinical • Machine learning • Acute Coronary Syndrome • Cardiovascular

OPTIMIZING ANTIPLATELET THERAPY AFTER CORONARY ARTERY BYPASS GRAFTING: A NETWORK META-ANALYSIS OF RANDOMIZED TRIALS (ACC 2026) - " We conducted a network meta-analysis of RCTs in adults undergoing CABG comparing aspirin, clopidogrel, ticagrelor, or their combinations. In CABG patients, DAPT was associated with greater graft patency but not lower mortality or ischemic events compared with aspirin, while ticagrelor plus aspirin was linked to higher bleeding risk."

Retrospective data • Cardiovascular • Myocardial Infarction

EARLY CORONARY ARTERY BYPASS GRAFTING IN STEMI PATIENTS PRE-LOADED WITH TICAGRELOR OR CLOPIDOGREL: CLINICAL AND SAFETY OUTCOMES (ACC 2026) - "In this single-center, retrospective cohort study, STEMI patients who received ticagrelor loading prior to early CABG had lower short-term mortality and no significant increase in TIMI major bleeding compared to those loaded with clopidogrel."

Clinical • Cardiovascular • Myocardial Infarction

WHEN THE AIR GETS THIN: TICAGRELOR-LINKED DYSPNEA IN MOUNTAIN POPULATIONS (ACC 2026) - "Ticagrelor is associated with substantially higher dyspnea rates at altitude compared to clopidogrel. Altitude may amplify ticagrelor's adverse respiratory effects, warranting consideration in antiplatelet selection for patients in high-altitude regions."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Pulmonary Disease